AVIRAGEN THERAPEUTICS INC. overview

...

...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

ATLANTA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended December 31, 2016, which is the second quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. “In looking to the 2017 calendar year, we have both near-term events and a broad vision driving the development of our antiviral pipeline. In the coming weeks, we have a key data readout from our...

ATLANTA, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV). The data indicate there was not a significant reduction in the primary endpoint,...

ATLANTA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m. ET to review the Company’s financial results for the three month period ended December 31, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results...

ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET in New York. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the...

ATLANTA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended September 30, 2016, which is the first quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. “Throughout the last quarter and in recent weeks, we have made significant progress advancing each of our Phase 2 antiviral clinical programs. Most notably, I am pleased to announce the completion...